Ascendis Pharma A (ASND) Other Accumulated Expenses (2017 - 2026)

Ascendis Pharma A (ASND) has 9 years of Other Accumulated Expenses data on file, last reported at $454.4 million in Q1 2026.

• For the quarter ending Q1 2026, Other Accumulated Expenses rose 65.27% year-over-year to $454.4 million; the trailing twelve-month figure through Mar 2026 stood at $454.4 million (up 65.27% YoY), and the FY2025 full-year result was $446.7 million, up 38.05% from the prior year.
• Other Accumulated Expenses improved to $454.4 million in Q1 2026, from $446.7 million in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $454.4 million in Q1 2026 to a low of $192.0 million in Q1 2024.
• A 4-year average of $319.2 million and a median of $297.9 million in 2024 frame the typical range for Other Accumulated Expenses.
• Across the five-year window, Other Accumulated Expenses surged 35.38% in 2025 and soared 65.27% in 2026, its largest moves.
• Tracing ASND's Other Accumulated Expenses over 4 years: stood at $200.3 million in 2023, then surged by 59.55% to $319.5 million in 2024, then jumped by 39.82% to $446.7 million in 2025, then rose by 1.71% to $454.4 million in 2026.
• Business Quant data shows ASND's Other Accumulated Expenses at $454.4 million in Q1 2026, $446.7 million in Q4 2025, and $381.7 million in Q3 2025.